Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BRC012
MIFTS: 71

Brucellosis

Categories: Rare diseases, Infectious diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Brucellosis

About this section

MalaCards integrated aliases for Brucellosis:

Name: Brucellosis 12 72 49 55 51 3 41 14 69
Undulant Fever 12 49 3
Mediterranean Fever 12 72
Gibraltar Fever 12 49
Malta Fever 12 49
Bang's Disease 12
Maltese Fever 12
Cyprus Fever 49
Rock Fever 49

Characteristics:

Orphanet epidemiological data:

55
brucellosis
Prevalence: <1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 55  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:11077
ICD9CM 34 023 023.9
MeSH 41 D002006
NCIt 46 C84602
Orphanet 55 ORPHA1304
MESH via Orphanet 42 D002006
UMLS via Orphanet 70 C0006309
ICD10 via Orphanet 33 A23.0 A23.1 A23.2 more
UMLS 69 C0006309
Sources

Summaries for Brucellosis

About this section
NIH Rare Diseases : 49 Brucellosis is a bacterial infection that spreads from animals to people via unpasteurized dairy products or by exposure to contaminated animal products or infected animals. Animals that are most commonly infected include sheep, cattle, goats, pigs, and dogs. Brucellosis can cause of range of signs and symptoms, some of which may persist or recur. Initial symptoms may include fever, sweats, malaise, anorexia, headache, fatigue, and/or pain in the muscles, joints, and/or back. Symptoms that may persist or recur include fevers, arthritis, swelling of the testicle and scrotum, swelling of the heart (endocarditis), neurologic symptoms (in up to 5% of cases), chronic fatigue, depression, and/or swelling of the liver or spleen. People who are in jobs or settings that increase exposure to the bacteria are at increased risk for infection. Antibiotics are used to treat brucellosis. Recovery may take a few weeks to several months, and relapses are common. Death from brucellosis is rare, occurring in no more than 2% of cases. Last updated: 12/12/2014

MalaCards based summary : Brucellosis, also known as undulant fever, is related to familial mediterranean fever and extrapulmonary tuberculosis, and has symptoms including fever, sweat and headache. An important gene associated with Brucellosis is MEFV (MEFV, Pyrin Innate Immunity Regulator), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Abatacept and Mycophenolate mofetil have been mentioned in the context of this disorder. Affiliated tissues include breast, testes and heart, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A primary bacterial infectious disease that is caused by the bacteria of the genus Brucella, when humans come in contact with contaminated animals or animal products or ingestion of infected food products. The disease has symptom fever, has symptom sweat, has symptom headache, has symptom back pain, has symptom physical weakness, has symptom joint pain and has symptom fatigue.

Wikipedia : 72 Brucellosis is a highly contagious zoonosis caused by ingestion of unpasteurized milk or undercooked... more...

Sources

Related Diseases for Brucellosis

About this section

Diseases related to Brucellosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 480)
# Related Disease Score Top Affiliating Genes
1 familial mediterranean fever 33.9 CRP IL1RN MEFV TNF
2 extrapulmonary tuberculosis 30.2 IFNG IL10 SLC11A1
3 purpura 30.2 CD40LG CRP TNF
4 q fever 30.2 CD40LG IFNG IL10 TLR4 TNF
5 campylobacteriosis 30.0 IFNG SLC11A1 TLR4
6 relapsing fever 30.0 CRP MEFV TNF
7 listeriosis 30.0 IL10 IL6 TNF
8 cat-scratch disease 30.0 CD40LG IFNG
9 spondylitis 29.9 CD40LG CRP IL6 TNF
10 acalculous cholecystitis 29.9 CD40LG CRP
11 tuberculous peritonitis 29.9 CRP IFNG TNF
12 infective endocarditis 29.8 CRP IL6 TNF
13 myocarditis 29.8 CD40LG IL6 TNF
14 granulomatous hepatitis 29.8 CD40LG CRP IL4
15 capillary leak syndrome 29.7 CXCL8 IL2 IL6
16 legionellosis 29.7 CD40LG TLR4 TNF
17 demyelinating disease 29.7 CD40LG IFNG IL10 TNF
18 endocarditis 29.6 CRP CXCL8 IL10 IL6 TNF
19 pertussis 29.6 IL10 IL6 TLR4 TNF
20 leptospirosis 29.5 CD40LG CRP CXCL8 IL10 IL6 TNF
21 hemorrhagic fever 29.4 CD40LG IFNG IL10 IL6 TNF
22 transverse myelitis 29.4 CXCL8 IL10 IL6 TNF
23 prostatitis 29.4 CXCL8 IL10 IL6 TNF
24 septic arthritis 29.4 CRP CXCL8 TLR4
25 reactive arthritis 29.4 CRP IFNG IL10 IL6 TNF
26 spondyloarthropathy 1 29.3 CD40LG CRP IL1RN TNF
27 pericarditis 29.3 CRP IL6 MEFV TNF
28 acute pyelonephritis 29.3 CRP CXCL8 IL10 IL6
29 pharyngitis 29.3 CRP CXCL8 MEFV
30 vasculitis 29.2 CD40LG CRP MEFV TNF
31 toxoplasmosis 29.1 CD40LG IFNG IL10 IL4 IL6 TLR4
32 uveitis 29.0 IFNG IL10 IL2RA IL4 TNF
33 typhoid fever 28.9 CRP IFNG IL6 SLC11A1 TLR4 TNF
34 exanthem 28.9 CD40LG CRP IL1RN IL2 TNF
35 mycobacterium tuberculosis 1 28.9 IFNG IL10 IL18 IL4 SLC11A1 TLR4
36 salmonellosis 28.9 IFNG IL18 SLC11A1 TLR4
37 meningitis 28.8 CD40LG CRP CXCL8 IFNG IL10 IL6
38 melioidosis 28.7 IFNG IL10 IL18 IL6 TLR4 TNF
39 pyelonephritis 28.7 CRP CXCL8 IL10 IL6 TLR4 TNF
40 helicobacter pylori infection 28.5 CXCL8 IFNG IL10 IL1RN TLR4 TNF
41 peritonitis 28.5 CRP CXCL8 IFNG IL10 IL6 MEFV
42 trypanosomiasis 28.4 CXCL8 IFNG IL10 IL2 IL4 IL6
43 acute pancreatitis 28.4 CRP CXCL8 IL10 IL18 IL6
44 pneumonia 28.3 CD40LG CRP CXCL8 IL10 IL6 TLR4
45 arthritis 28.2 CXCL8 IFNG IL10 IL18 IL1RN IL6
46 hemophagocytic lymphohistiocytosis 28.2 CXCL8 IFNG IL10 IL18 IL2RA TNF
47 chlamydia 28.1 CD40LG CRP CXCL8 IFNG IL10 IL6
48 autoimmune disease 27.5 CD40LG IFNG IL10 IL1RN IL2 IL2RA
49 familial mediterranean fever, autosomal dominant 12.4
50 brucella melitensis brucellosis 12.3

Graphical network of the top 20 diseases related to Brucellosis:



Diseases related to Brucellosis
Sources

Symptoms & Phenotypes for Brucellosis

About this section

Symptoms:

12
  • • fever
  • • sweat
  • • headache
  • • back pain
  • • physical weakness
  • • joint pain
  • • fatigue

GenomeRNAi Phenotypes related to Brucellosis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 TNF CD40LG CXCL8 IL10 IL18 IL2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 TNF CD40LG CXCL8 IL10 IL18 IL2

MGI Mouse Phenotypes related to Brucellosis:

43 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.31 CD40LG IFNG IL10 IL18 IL1RN IL2
2 immune system MP:0005387 10.3 TLR4 TNF CD40LG CRP IFNG IL10
3 cellular MP:0005384 10.29 CD40LG IFNG IL10 IL18 IL1RN IL2
4 homeostasis/metabolism MP:0005376 10.29 CD40LG CRP IFNG IL10 IL18 IL1RN
5 cardiovascular system MP:0005385 10.26 TNF CD40LG CRP IFNG IL10 IL18
6 growth/size/body region MP:0005378 10.25 IFNG IL10 IL18 IL1RN IL2 IL2RA
7 digestive/alimentary MP:0005381 10.24 IFNG IL10 IL18 IL2 IL2RA IL4
8 mortality/aging MP:0010768 10.18 SLC11A1 TLR4 TNF CD40LG IFNG IL10
9 endocrine/exocrine gland MP:0005379 10.13 CD40LG IFNG IL10 IL2 IL2RA IL4
10 integument MP:0010771 10.13 IL1RN IL4 IL6 MEFV TLR4 TNF
11 liver/biliary system MP:0005370 10.01 IFNG IL10 IL2 IL4 IL6 MEFV
12 reproductive system MP:0005389 9.96 CD40LG IFNG IL10 IL1RN IL2 IL4
13 neoplasm MP:0002006 9.87 IFNG IL10 IL2 IL6 SLC11A1 TLR4
14 respiratory system MP:0005388 9.76 IFNG IL10 IL2 IL2RA IL4 IL6
15 skeleton MP:0005390 9.61 IFNG IL10 IL1RN IL4 IL6 MEFV
16 vision/eye MP:0005391 9.28 IFNG IL10 IL18 IL2 IL2RA IL4
Sources

Drugs & Therapeutics for Brucellosis

About this section

Drugs for Brucellosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 766)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Abatacept Approved Phase 4 332348-12-6 10237
2
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
3
Mycophenolic acid Approved Phase 4 24280-93-1 446541
4
Tacrolimus Approved, Investigational Phase 4,Phase 3 104987-11-3 445643 439492
5
Atenolol Approved Phase 4 29122-68-7 2249
6
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
7
Methyltestosterone Approved Phase 4,Phase 3 58-18-4 6010
8
Testosterone Approved, Investigational Phase 4,Phase 3 58-22-0 6013
9
Heroin Approved, Illicit, Investigational Phase 4 561-27-3 5462328
10
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
11
Cobicistat Approved Phase 4 1004316-88-4
12
Efavirenz Approved, Investigational Phase 4,Phase 3 154598-52-4 64139
13
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
14
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
15
Colchicine Approved Phase 4,Phase 3,Phase 2,Phase 1 64-86-8 2833 6167
16
Adenosine Approved, Investigational Phase 4,Phase 2 58-61-7 60961
17
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
18
Maraviroc Approved, Investigational Phase 4,Phase 2,Phase 3 376348-65-1 3002977
19
Daptomycin Approved, Investigational Phase 4 103060-53-3 16129629
20
Telavancin Approved Phase 4 372151-71-8
21
Ranolazine Approved, Investigational Phase 4 95635-55-5, 142387-99-3 56959
22
Oseltamivir Approved Phase 4,Phase 3 196618-13-0, 204255-11-8 65028
23
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
24
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
25
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
26
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 1 616-91-1 12035
27
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
28
Nicotine Approved Phase 4 54-11-5 89594 942
29
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
30
Vancomycin Approved Phase 4 1404-90-6 14969 441141
31
Zinc Approved, Investigational Phase 4,Phase 2 7440-66-6 32051 23994
32
Citalopram Approved Phase 4,Phase 3,Phase 2 59729-33-8 2771
33
Donepezil Approved Phase 4,Phase 2 120014-06-4 3152
34
Norepinephrine Approved Phase 4,Phase 2 51-41-2 439260
35
Memantine Approved, Investigational Phase 4,Phase 2 19982-08-2 4054
36
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
37
Amodiaquine Approved, Investigational Phase 4,Phase 3 86-42-0 2165
38
Artesunate Approved, Investigational Phase 4,Phase 3 88495-63-0 5464098 6917864
39
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 5195 26757
40
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
41
Dapsone Approved, Investigational Phase 4 80-08-0 2955
42
Celecoxib Approved, Investigational Phase 4,Phase 2 169590-42-5 2662
43
Ibuprofen Approved Phase 4 15687-27-1 3672
44
Naproxen Approved, Vet_approved Phase 4,Phase 2 22204-53-1 156391 1302
45
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
46
Ramipril Approved Phase 4 87333-19-5 5362129
47
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
48
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
49
Sertraline Approved Phase 4 79617-96-2 68617
50
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3 50-02-2 5743

Interventional clinical trials:

(show top 50) (show all 914)

# Name Status NCT ID Phase Drugs
1 VeinViewer Assisted Intravenous Catheter Placement in the Pediatric Emergency Department Unknown status NCT00468065 Phase 4
2 Comparison of NODAT in Kidney Transplant Patients Receiving Belatacept Versus Standard Immunosuppression Unknown status NCT01875224 Phase 4 Belatacept;Tacrolimus
3 Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina. Unknown status NCT01397994 Phase 4 Nicorandil;Atenolol
4 Injection Assistance Device Versus Manual Injections for Delivery of Dermal Fillers Unknown status NCT01492140 Phase 4
5 Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men Unknown status NCT01699178 Phase 4 Oral testosterone undecanoate;Transdermal testosterone gel (AndroGel)
6 Nasal Naloxone for Narcotic Overdose Unknown status NCT01912573 Phase 4 Intranasal (IN) naloxone;Intravenous (IV) naloxone;Intramuscular (IM) naloxone;Intraosseus (IO) naloxone
7 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
8 Sleep and Cognition After Atripla to Stribild Switch Unknown status NCT02283060 Phase 4 Stribild;Atripla
9 Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD) Unknown status NCT01272531 Phase 4 Mood stabilizer treatment
10 The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With FMF Completed NCT02602028 Phase 4 colchicine
11 A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac) Completed NCT01449006 Phase 4 Maraviroc
12 Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD) Completed NCT00663403 Phase 4 Daptomycin
13 Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5 Completed NCT02392208 Phase 4 Telavancin
14 Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation Completed NCT00578968 Phase 4 Tiotropium;Placebo
15 Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients Completed NCT01435174 Phase 4 Ranolazine
16 Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD) Completed NCT01048879 Phase 4
17 Pharmacokinetics of Ertapenem in Continuous Venovenous Hemodialysis Completed NCT00877370 Phase 4 ertapenem
18 The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems Completed NCT00988117 Phase 4 Rivastigmine Patch 9.5 cm2
19 Integrated Dual Exercise and Lexiscan Positron Emission Tomography: IDEALPET Completed NCT01109992 Phase 4 Exercise plus Regadenoson (Lexercise);Regadenoson (Lexiscan)
20 Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease Completed NCT02476526 Phase 4 Low Volume iso-osmolar non-ionic radio contrast medium;Acetylcysteine Inhalation;Sodium Bicarbonate Solution
21 Rural Andhra Pradesh Cardiovascular Prevention Study (RAPCAPS) Completed NCT00263393 Phase 4 ASA, Atenolol, hydrochlorothiazide, ACE inhibitor, Statin
22 Helping Those With Mental Illness Quit Smoking Completed NCT01783912 Phase 4 Nicotine Patch
23 Ankle Block Versus Popliteal Fossa Block as Primary Anesthesia for Forefoot Surgical Procedures Completed NCT01376960 Phase 4
24 ULTRA Study for Pacemaker Patients Completed NCT00133289 Phase 4
25 Effect of Age on Latanoprost 0.005% in Patients With Glaucoma Completed NCT00224289 Phase 4 Latanoprost 0.005%
26 Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas Completed NCT00295178 Phase 4 Daptomycin;Vancomycin
27 Chronic Insertional Achilles Tendonitis Treated With or Without Flexor Hallucis Longus Tendon Transfer Completed NCT00950053 Phase 4
28 Needle Length In Obese Insulin-Using Diabetic Subjects Completed NCT00541372 Phase 4
29 Antidepressant Medication Plus Donepezil for Treating Late-life Depression Completed NCT00177671 Phase 4 Escitalopram;Donepezil;Venlafaxine;Placebo;Duloxetine
30 Foot and Ankle Clinic Application for Liposomal Related Anesthetic Completed NCT02586077 Phase 4 Exparel
31 Comparative Performance of PureVision, Acuvue Oasys and O2Optix Completed NCT00640341 Phase 4
32 Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Completed NCT00545974 Phase 4 memantine;Placebo pill
33 Safety and Acceptability of the PrePexâ„¢ Device for Male Circumcision in Zambia Completed NCT01844102 Phase 4
34 Study of Long-term Peg Intron vs. Colchicine in Non-responders. Completed NCT00179413 Phase 4 PEG -Intron;Colchicine
35 Restricting the Use of Artesunate Plus Amodiaquine Combination Therapy to Malaria Cases Confirmed by a Dipstick Test: A Cluster Randomised Control Trial Completed NCT00832754 Phase 4
36 Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression Completed NCT00531947 Phase 4 Selegiline Transdermal System;Placebo
37 Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo Completed NCT01308619 Phase 4 Doxycycline
38 Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in Treating Subjects With Acne Who Have G6PD Deficiency Completed NCT00243542 Phase 4 ACZONE Gel, 5%;Vehicle
39 Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen Completed NCT00346216 Phase 4 celecoxib;Ibuprofen;Naproxen
40 Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo. Completed NCT00153101 Phase 4 Telmisartan;Combination of Telmisartan and Ramipril;Ramipril
41 Corticosteroids With Vedolizumab in Crohn's Disease Recruiting NCT02324699 Phase 4 Prednisone;Placebo;Vedolizumab
42 International Study to Predict Optimised Treatment - in Depression Recruiting NCT00693849 Phase 4 Escitalopram;Sertraline;Venlafaxine-XR
43 PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Recruiting NCT00867815 Phase 4 Diagnostic procedures
44 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
45 AAA Registry: Clinical Outcomes of Highly Angulated anatomY Treated With the Aorfixâ„¢ Stent Graft Recruiting NCT02480595 Phase 4
46 Multimodal Analgesia vs. Routine Care Pain Management for Lumbar Spine Fusion Surgery: A Prospective Randomized Study Recruiting NCT02202369 Phase 4
47 A Prospective Study of the InterFuse T(tm), Recruiting NCT02678130 Phase 4
48 Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis Recruiting NCT02308111 Phase 4 Obeticholic Acid (OCA);Placebo
49 Zoster Eye Disease Study Recruiting NCT03134196 Phase 4 Masked Placebo;Masked Oral Valacyclovir
50 Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial Recruiting NCT02699645 Phase 4 telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg;Placebo

Search NIH Clinical Center for Brucellosis

Cochrane evidence based reviews: brucellosis

Sources

Genetic Tests for Brucellosis

About this section
Sources

Anatomical Context for Brucellosis

About this section

MalaCards organs/tissues related to Brucellosis:

38
Breast, Testes, Heart, Lung, Prostate, Brain, Liver
Sources

Publications for Brucellosis

About this section

Articles related to Brucellosis:

(show top 50) (show all 1644)
# Title Authors Year
1
Increased psoriasis frequency in patients with familial Mediterranean fever. ( 29363386 )
2018
2
A 44-Year-Old Female with Familial Mediterranean Fever, Cardiomyopathy and End Stage Renal Disease. ( 29265632 )
2018
3
Fatigue in pediatric patients with familial Mediterranean fever. ( 29322855 )
2018
4
Association between human brucellosis and adverse pregnancy outcome: a cross-sectional population-based study. ( 29344838 )
2018
5
Boundaries between familial Mediterranean fever and juvenile spondyloarthritis: Analysis of three French retrospective cohorts. ( 29452306 )
2018
6
Evaluation of the effects of miRNAs in familial Mediterranean fever. ( 29442258 )
2018
7
Familial Mediterranean fever mutations are hypermorphic mutations that specifically decrease the activation threshold of the Pyrin inflammasome. ( 29040788 )
2018
8
Comparison of early versus late onset familial Mediterranean fever. ( 29314707 )
2018
9
Brucellosis in West and Central Africa: A review of the current situation in a changing landscape of dairy cattle systems. ( 29287761 )
2018
10
Spastic paraparesis and sensorineural hearing loss: keep brucellosis in mind. ( 29406895 )
2018
11
Lack of clear and univocal genotype-phenotype correlation in Familial Mediterranean Fever patients: A systematic review. ( 29393966 )
2018
12
Canakinumab treatment in children with familial Mediterranean fever: report from a single center. ( 29450637 )
2018
13
Effect of oral Colchicine on Peripapillary retinal nerve fiber layer thickness in patients with familial Mediterranean fever. ( 29402238 )
2018
14
Canakinumab treatment in renal transplant recipients with familial Mediterranean fever. ( 29446001 )
2018
15
Brucellosis remains a neglected disease in the developing world: a call for interdisciplinary action. ( 29325516 )
2018
16
Brucellosis Risk in Urban and Agro-pastoral Areas in Tanzania. ( 29344824 )
2018
17
Atypical familial Mediterranean fever developed in a long-term hemodialysis patient. ( 29345845 )
2018
18
A Case of Familial Mediterranean Fever Having Intermittent Leukopenia. ( 29240030 )
2018
19
Very Rare Presentation of Cerebrovascular Accident in 20-Year-Old Man With Familial Mediterranean Fever-Case Report. ( 29326535 )
2018
20
Hematologic Manifestations of Brucellosis in Children. ( 29329166 )
2018
21
PFAPA Syndrome in a Population with Endemic Familial Mediterranean Fever. ( 29031862 )
2018
22
An autoimmune disease-associated risk variant in the<i>TNFAIP3</i>gene plays a protective role in brucellosis that is mediated by the NF-kappa B signaling pathway. ( 29343543 )
2018
23
Trend Analysis and Affecting Components of Human Brucellosis Incidence During 2006 to 2016. ( 29416212 )
2018
24
Effects of mating patterns on genealogical trees: Assessment of the high carrier rate of Familial Mediterranean Fever in rural Israeli districts. ( 29382538 )
2018
25
Rifampicin-Induced Fever in a Patient with Brucellosis: A Case Report. ( 29427095 )
2018
26
MEFV gene testing may guide physicians for early diagnosis of familial Mediterranean fever. ( 29314663 )
2018
27
Serological study of brucellosis in Argentine Creole sheep. ( 29310845 )
2018
28
Evaluation of three serological tests for diagnosis of bovine brucellosis in smallholder farms in Pakistan by estimating sensitivity and specificity using Bayesian latent class analysis. ( 29290297 )
2018
29
Knowledge, attitudes, and practices (KAP) related to brucellosis and factors affecting knowledge sharing on animal diseases: a cross-sectional survey in the dry zone of Sri Lanka. ( 29392550 )
2018
30
Seroepidemiology of Human Brucellosis Among Blood Donors in Southern Ethiopia: Calling Attention to a Neglected Zoonotic Disease. ( 28077743 )
2017
31
Isolated splenic abscess in brucellosis. ( 28473914 )
2017
32
Reduced IFN-I^ Production in Chronic Brucellosis Patients. ( 28919584 )
2017
33
Does Helicobacter pylori infection play a role in susceptibility to Brucellosis? ( 28890508 )
2017
34
Epidemiology of bovine brucellosis in Costa Rica: Lessons learned from failures in the control of the disease. ( 28797045 )
2017
35
Is there any difference regarding atopy between children with familial Mediterranean fever and healthy controls? ( 28465037 )
2017
36
Effect of hydroxychloroquine on treatment and recurrence of acute brucellosis: a single-blind randomized clinical trial. ( 28826825 )
2017
37
Association of amyloidosis cutis dyschromica and familial Mediterranean fever. ( 29267436 )
2017
38
Prevalence of bovine brucellosis in slaughtered cattle and barriers to better protection of abattoir workers in Ibadan, South-Western Nigeria. ( 29255538 )
2017
39
MicroRNA-204-3p inhibits lipopolysaccharide-induced cytokines in familial Mediterranean fever via the phosphoinositide 3-kinase I^ pathway. ( 29294109 )
2017
40
Differential Expression of miR-4520a Associated With Pyrin Mutations in Familial Mediterranean Fever (FMF). ( 27636101 )
2017
41
Brucellosis in Patients with Crimean-Congo Hemorrhagic Fever. ( 29367923 )
2017
42
Fludarabine is effective in treating refractory hemophagocytic lymphohistiocytosis with brucellosis. ( 28378406 )
2017
43
Brucellosis and thrombosis of the inferior vena cava. ( 27871206 )
2017
44
Intestinal brucellosis associated with celiac artery and superior mesenteric artery stenosis and with ileum mucosa and submucosa thickening: A case report. ( 28079834 )
2017
45
Documenting the absence of brucellosis in cattle, goats and dogs in a "One Health" interface in the Mnisi community, Limpopo, South Africa. ( 29274056 )
2017
46
Human Brucellosis in Rural Uganda: Clinical Manifestations, Diagnosis, and Comorbidities at Kabale Regional Referral Hospital, Kabale, Uganda. ( 29255733 )
2017
47
A seroprevalence and relationship survey of brucellosis between pregnant women and women with spontaneous abortion in Iran. ( 29445671 )
2017
48
Brucellosis in livestock and wildlife: zoonotic diseases without pandemic potential in need of innovative one health approaches. ( 28904791 )
2017
49
The M694I/M694I genotype: A genetic risk factor of AA-amyloidosis in a group of Algerian patients with familial Mediterranean fever. ( 27956278 )
2017
50
Massive Pericardial Effusion and Tamponade Can Be a First Sign of Familial Mediterranean Fever. ( 28763406 )
2017
Sources

Variations for Brucellosis

About this section
Sources

Expression for Brucellosis

About this section
Search GEO for disease gene expression data for Brucellosis.
Sources

Pathways for Brucellosis

About this section

Pathways related to Brucellosis according to GeneCards Suite gene sharing:

(show top 50) (show all 85)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 62
Show member pathways
 14.01 CD40LG CRP CXCL8 IFNG IL10 IL18
2
ERK Signaling 60
Show member pathways
 13.86 CD40LG CXCL8 IL10 IL18 IL2 IL2RA
3
PEDF Induced Signaling 60
Show member pathways
 13.76 CD40LG CXCL8 IFNG IL10 IL18 IL2
4
TGF-Beta Pathway 60
Show member pathways
 13.62 CXCL8 IFNG IL10 IL18 IL2 IL2RA
5
Akt Signaling 60
Show member pathways
 13.52 CD40LG CXCL8 IL10 IL18 IL2 IL2RA
6
Cytokine Signaling in Immune system 62
Show member pathways
 13.43 CD40LG CXCL8 IFNG IL10 IL18 IL1RN
7
PAK Pathway 60
Show member pathways
 13.42 CD40LG CXCL8 IL10 IL18 IL2 IL2RA
8
IL-2 Pathway 60
Show member pathways
 13.23 IFNG IL2 IL2RA IL4 TLR4 TNF
9
Toll-Like receptor Signaling Pathways 61
Show member pathways
 13.09 CXCL8 IL18 IL1RN IL6 MEFV TLR4
10
PI3K-Akt signaling pathway 36
Show member pathways
 13.04 IL2 IL2RA IL4 IL6 TLR4 TNF
11
Allograft rejection 1 36
Show member pathways
 12.95 CD40LG CXCL8 IFNG IL10 IL2 IL2RA
12
Pathways in cancer 36
12.93 CXCL8 IFNG IL2 IL2RA IL4 IL6
13
Influenza A 36
Show member pathways
 12.89 CXCL8 IFNG IL18 IL2 IL2RA IL4
14
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 61
Show member pathways
 12.82 IL2 IL2RA IL4 IL6 TNF
15
RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways 62
Show member pathways
 12.78 CXCL8 IFNG IL18 IL6 TNF
16
Immune response NFAT in immune response 21
Show member pathways
 12.78 CD40LG IFNG IL10 IL18 IL2 IL2RA
17
NF-KappaB Family Pathway 60
Show member pathways
 12.76 CD40LG IL2 IL6 TLR4 TNF
18
Immune response IL-23 signaling pathway 21
Show member pathways
 12.72 IFNG IL10 IL18 IL2 IL6 TNF
19
Toll-like receptor signaling pathway 1 36
Show member pathways
 12.68 CXCL8 IFNG IL10 IL2 IL6 TLR4
20
NF-kappaB Signaling 4
12.68 CD40LG IFNG IL10 IL1RN IL2 IL2RA
21
Th17 cell differentiation 36
Show member pathways
 12.65 IFNG IL10 IL18 IL2 IL2RA IL4
22
T cell receptor signaling pathway 36
Show member pathways
 12.59 CD40LG IFNG IL10 IL2 IL4 IL6
23
Kaposi's sarcoma-associated herpesvirus infection 36
Show member pathways
 12.58 CXCL8 IL6 TLR4 TNF
24
Immune response Role of DAP12 receptors in NK cells 21
Show member pathways
 12.54 IFNG IL2 IL4 TNF
25
Jak-STAT signaling pathway (KEGG) 36
Show member pathways
 12.53 IFNG IL10 IL2 IL2RA IL4 IL6
26
Selenium Micronutrient Network 1
Show member pathways
 12.51 CRP IFNG IL2 IL4 IL6 TNF
27
HTLV-I infection 36
12.46 IL2 IL2RA IL6 TNF
28
IL-17 Family Signaling Pathways 61
Show member pathways
 12.45 CXCL8 IFNG IL4 IL6 TNF
29
Toxoplasmosis 36
Show member pathways
 12.42 CD40LG IFNG IL10 IL4 TLR4 TNF
30
Toll Comparative Pathway 60
Show member pathways
 12.41 CXCL8 IFNG IL6 TLR4 TNF
31
Tuberculosis 36
12.4 IFNG IL10 IL18 IL6 TLR4 TNF
32
Bacterial infections in CF airways 21
Show member pathways
 12.35 CXCL8 IFNG IL4 IL6 TLR4 TNF
33
Diseases associated with the TLR signaling cascade 62
Show member pathways
 12.33 CXCL8 IL6 TLR4 TNF
34
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.32 CXCL8 IL10 IL1RN IL6 TNF
35
Colorectal Cancer Metastasis 60
12.26 IFNG IL6 TLR4 TNF
36
Interleukin-4 and 13 signaling 62
12.16 CXCL8 IL10 IL18 IL4 IL6 TNF
37
IL12-mediated signaling events 1
Show member pathways
 12.15 IFNG IL18 IL2 IL2RA IL4
38
Spinal Cord Injury 1
12.13 CXCL8 IFNG IL2 IL4 IL6 TLR4
39
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 61
12.1 IFNG IL10 IL2 IL2RA IL4 IL6
40
Amoebiasis 36
12.07 CXCL8 IFNG IL10 IL6 TLR4 TNF
41
IL27-mediated signaling events 1
Show member pathways
 12.04 IFNG IL10 IL18 IL2 IL6 TLR4
42
Hematopoietic cell lineage 36
12.02 IL2RA IL4 IL6 TNF
43
Salmonella infection (KEGG) 36
12.02 CXCL8 IFNG IL18 IL6 TLR4
44
Rheumatoid arthritis 36
12.02 CXCL8 IFNG IL18 IL6 TLR4 TNF
45
NF-kappa B signaling pathway 36
12.01 CD40LG CXCL8 TLR4 TNF
46
Jak-Stat Signaling Pathway (sino) 63
12.01 IFNG IL10 IL2 IL2RA IL6
47
Corticotropin-releasing hormone signaling pathway 1
12 CXCL8 IL18 IL2 TLR4
48
Th17 Differentiation Pathway 61
Show member pathways
 11.99 IFNG IL4 IL6 TLR4
49
Glucocorticoid receptor regulatory network 1
11.99 CXCL8 IFNG IL2 IL4 IL6
50
Immune response IFN alpha/beta signaling pathway 21
Show member pathways
 11.97 CXCL8 IFNG IL10 IL18 IL2 IL4
Sources

GO Terms for Brucellosis

About this section

Cellular components related to Brucellosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intracellular GO:0005622 9.81 CD40LG CXCL8 IFNG IL1RN IL2 IL2RA
2 extracellular region GO:0005576 9.7 CD40LG CRP CXCL8 IFNG IL10 IL18
3 external side of plasma membrane GO:0009897 9.56 CD40LG IL2RA TLR4 TNF
4 extracellular space GO:0005615 9.36 CD40LG CRP CXCL8 IFNG IL10 IL18

Biological processes related to Brucellosis according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.98 IL10 SLC11A1 TLR4 TNF
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.92 CD40LG IL6 TLR4 TNF
3 positive regulation of gene expression GO:0010628 9.91 CRP IFNG IL18 IL6 SLC11A1 TLR4
4 positive regulation of DNA binding transcription factor activity GO:0051091 9.9 IL10 IL6 TNF
5 defense response to Gram-positive bacterium GO:0050830 9.9 CRP IL6 TNF
6 defense response to Gram-negative bacterium GO:0050829 9.87 IL6 SLC11A1 TLR4
7 negative regulation of inflammatory response GO:0050728 9.87 IL10 IL2 IL2RA MEFV
8 B cell differentiation GO:0030183 9.86 CD40LG IL10 IL4
9 positive regulation of inflammatory response GO:0050729 9.86 IL18 IL2 TLR4
10 positive regulation of smooth muscle cell proliferation GO:0048661 9.85 IL18 IL6 TNF
11 humoral immune response GO:0006959 9.85 IFNG IL6 TNF
12 cellular response to lipopolysaccharide GO:0071222 9.85 CXCL8 IL10 IL6 TLR4 TNF
13 regulation of receptor activity GO:0010469 9.85 CD40LG CXCL8 IFNG IL10 IL18 IL1RN
14 positive regulation of interleukin-6 production GO:0032755 9.83 IL6 TLR4 TNF
15 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.83 IFNG IL18 IL2 IL6
16 positive regulation of nitric oxide biosynthetic process GO:0045429 9.82 IFNG TLR4 TNF
17 positive regulation of B cell proliferation GO:0030890 9.81 IL2 IL4 TLR4
18 response to glucocorticoid GO:0051384 9.8 IL10 IL1RN IL6 TNF
19 lipopolysaccharide-mediated signaling pathway GO:0031663 9.79 IL18 TLR4 TNF
20 positive regulation of activated T cell proliferation GO:0042104 9.77 IL18 IL2 IL2RA
21 negative regulation of interleukin-6 production GO:0032715 9.77 IL10 TLR4 TNF
22 immune response GO:0006955 9.77 CD40LG CXCL8 IFNG IL10 IL18 IL1RN
23 positive regulation of interleukin-12 production GO:0032735 9.76 CD40LG IFNG TLR4
24 positive regulation of NF-kappaB import into nucleus GO:0042346 9.75 IL18 TLR4 TNF
25 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.73 IFNG TNF
26 positive regulation of macrophage activation GO:0043032 9.73 IL10 TLR4
27 negative regulation of growth of symbiont in host GO:0044130 9.73 IL10 TNF
28 positive regulation of interleukin-17 production GO:0032740 9.73 IL18 IL2
29 positive regulation of chemokine production GO:0032722 9.73 IL6 TLR4 TNF
30 response to molecule of bacterial origin GO:0002237 9.72 CXCL8 IL10
31 negative regulation of interleukin-12 production GO:0032695 9.72 IL10 MEFV
32 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.72 IL10 TNF
33 positive regulation of immunoglobulin secretion GO:0051024 9.72 IL2 IL6
34 positive regulation of T cell differentiation GO:0045582 9.72 IL2 IL2RA IL4
35 positive regulation of T cell proliferation GO:0042102 9.72 CD40LG IL2 IL2RA IL4 IL6
36 T-helper 1 type immune response GO:0042088 9.71 IL18 TLR4
37 interferon-gamma production GO:0032609 9.71 IL18 TLR4
38 neutrophil activation GO:0042119 9.71 CXCL8 IL18
39 negative regulation of interleukin-17 production GO:0032700 9.71 IFNG TLR4
40 regulation of regulatory T cell differentiation GO:0045589 9.71 IFNG IL2 IL2RA
41 macrophage activation GO:0042116 9.7 SLC11A1 TLR4
42 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.7 IL10 IL1RN
43 positive regulation of isotype switching to IgG isotypes GO:0048304 9.7 IL2 IL4
44 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.69 TLR4 TNF
45 endothelial cell apoptotic process GO:0072577 9.69 IL10 TNF
46 negative regulation of lymphocyte proliferation GO:0050672 9.67 IL2 IL2RA
47 negative regulation of cytokine secretion involved in immune response GO:0002740 9.67 IL10 TNF
48 positive regulation of tissue remodeling GO:0034105 9.66 IL18 IL2
49 regulation of immunoglobulin secretion GO:0051023 9.66 CD40LG TNF
50 regulation of isotype switching GO:0045191 9.65 IL10 IL4

Molecular functions related to Brucellosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.32 CD40LG CXCL8 IFNG IL10 IL18 IL1RN
2 growth factor activity GO:0008083 9.26 IL10 IL2 IL4 IL6
3 protein binding GO:0005515 10 CD40LG CRP CXCL8 IFNG IL10 IL18
Sources

Sources for Brucellosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....